language_icon
EN
HI

Hester Biosciences Share price

HESTERBIO

1831.4

91.20 (5.24%)
NSE
BSE
Last updated on 15 May, 2026 | 15:51 IST
Today's High

1990.00

Today's Low

1732.90

52 Week Low

1239.30

52 Week High

2350.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Hester Biosciences Chart

Hester Biosciences Share Key Metrics

Volume
1.88 L
Market Cap
1557.95 CR
LTQ@LTP
20@1831.40
ATP
1922.1
Var Margin
19.4 %
Circuit Range
1392.2-2088.2
Delivery %
48.47 %
Value
36.10 CR
ASM/GSM
No
Market Lot
1

Summary

Hester Biosciences share price is ₹1831.4 as of 17 May, 2026. The stock Hester Biosciences intraday movement has stayed between ₹1732.90 and ₹1990.00, while on a 52-week basis,Hester Biosciences price 52 week high is ₹2350.00 & its 52 week low is ₹1239.30.
In terms of trading activity, Hester Biosciences has recorded a volume of 187800 shares, The Hester Biosciences has a market cap of ₹8506865 CR. The stock’s Average Traded Price (ATP) stands at ₹1922.10, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 20 @ ₹1831.40.
Hester Biosciences operates within a circuit range of ₹1392.20 – ₹2088.20, with a Value of ₹36.10 CR. The Delivery Percentage for the day is 48.47%. Additionally, Hester Biosciences currently falls under the No framework, and trades with a market lot size of 1.

Hester Biosciences Fundamentals

View More
P/E Ratio

28.04

P/B Ratio

4.51

Div. Yield

0.38

Sector P/E

71.32

Sector P/B

3.47

Sec. Div. Yield

0.56

Hester Biosciences Resistance and Support

Pivot 1719.63

Resistance

First Resistance

1769.56

Second Resistance

1798.93

Third Resistance

1848.86

Support

First Support

1690.26

Second Support

1640.33

Third Support

1610.96

Hester Biosciences Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

53.73%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0.38%

Domestic Institutional Investors

0%

Retail

45.89%

Others

0%

Total Promoters
MAR '26
53.73%

Hester Biosciences Corporate Actions

DateAgenda
2026-05-15Audited Results & Final Dividend
2026-01-30Quarterly Results
2025-11-12Quarterly Results
2025-08-01Quarterly Results
2025-05-09Audited Results & Final Dividend
2025-01-30Quarterly Results

Hester Biosciences News

Hester Biosciences Ltd - 524669 - Announcement Under Regulation 30 (LODR) - Corporate Presentation

Hester Biosciences released its Corporate Presentation for FY26. The presentation highlights strong financial growth with consolidated net profit increasing by 99% to Rs.57.48 crore and consolidated revenue rising by 7% to Rs.332.60 crore.
May 15 2026 17:05:00

Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Hester Biosciences informed that the audio recording of its earnings conference call for the financial results of Q4 FY26 is now available on the company website for investor access.
May 15 2026 16:05:00

Hester Biosciences Ltd - 524669 - Disclosure On Board Approval For Re-Classification Request Under Regulation 31A Of SEBI Listing Regulations

Hester Biosciences board approved the request for re-classification of promoters Mr. Ravin Gandhi and Ms. Bela Gandhi to the 'public' shareholder category. This re-classification is contingent upon receiving a No Objection Certificate from the stock exchanges.
May 15 2026 12:05:00

Hester Biosciences Ltd - 524669 - Intimation Of Receipt Of Requests For Reclassification From The 'Promoters' To The 'Public' Category In Accordance With Regulation 31A Of SEBI Listing Regulations

Hester Biosciences received requests from two promoters, Mr. Ravin Gandhi (4.74% stake) and Ms. Bela Gandhi (4.71% stake), for reclassification of their shareholdings from 'Promoter' to 'Public' category. This formalizes their passive investment status and lack of management involvement.
May 15 2026 12:05:00

Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Change in Management

Hester Biosciences re-appointed Ms. Priya Gandhi as Executive Director for a three-year term, effective October 28, 2026. She is the daughter of CEO & MD Rajiv Gandhi and has been instrumental in driving the company's strategic direction.
May 15 2026 12:05:00

Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Hester Biosciences reported strong Q4 FY26 consolidated results, with revenue growing 22% YoY and net profit soaring 974% YoY to INR 165.46 million. The board also recommended a dividend of INR 11 per equity share for FY26.
May 15 2026 12:05:00

Hester Biosciences Ltd - 524669 - Board Meeting Outcome for Outcome Of Board Meeting Held On 15 May 2026

Hester Biosciences reported Q4 FY26 cons. revenue of ₹100.11 crores (up 22% YoY) and net profit of ₹16.55 crores (up 974% YoY). The board also recommended a ₹11 dividend per share for FY26 and divested 43.81% stake in subsidiary TLPL.
May 15 2026 11:05:00

Hester Biosciences Ltd - 524669 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Hester Biosciences is scheduling an earnings conference call on May 15, 2026, at 2:00 PM IST. Management will discuss the financial performance for Q4 and the full fiscal year ended March 31, 2026, following the results announcement.
May 11 2026 16:05:00

Hester Biosciences Ltd - 524669 - Board Meeting Intimation for Financial Results And Dividend

Hester Biosciences' Board of Directors will hold a meeting on May 15, 2026. The agenda includes considering the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and the declaration of a dividend for the financial year 2025-26.
May 08 2026 16:05:00

Hester Biosciences Limited

Hester Biosciences' promoters and promoter group declared no direct or indirect encumbrance on their shareholding for the financial year ended March 31, 2026. This declaration was made by Mr. Rajiv Gandhi, a person acting in concert, and is a compliance filing.
Apr 23 2026 14:04:00
Read More

About Hester Biosciences

NSE : 7048  
BSE : 524669  
ISIN : INE782E01017  

Hester Biosciences Management

NamePosition
Bhupendra GandhiChairman
Rajiv GandhiManaging Director & Chief Executive Officer
View More

Hester Biosciences FAQs

The Buying Price of Hester Biosciences share is 1831.4 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Hester Biosciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Hester Biosciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Hester Biosciences shares is 28.04. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Hester Biosciences shares is 4.51. Useful to assess the stock's value relative to its book value.

To assess Hester Biosciences’s valuation compare Sector P/E, P/B which are 71.32 & 3.47 with sector averages, along with growth rates and financial metrics.

The Market Cap of Hester Biosciences is 1557.95 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Hester Biosciences share price is 2350.00 & 1239.30. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Hester Biosciences belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost